3[1]American Thoracic Society.Guidelines for the management of adults with community acquired pneumonia[J].Am J Crit Care Med,2001,163(7):1730-1754.
4[2]American Thoracic Society,Infectious Diseases Society of America.Guidelines for the management of adults with hospital-acquired,ventilator-associated,and healthcare-associated pneumonia[J].Am J Respir Crit Care,2005,171(4):388-416.
5[3]Paganin F,Lilienthal F,Bourdin A,et al.Severe community-acquired pneumonia:assessment of microbial aetiology as mortality factor[J].Eur Respir J,2004,24(5):779-785.
6[4]Rello J,Bodi M,Mariscal D,et al.Microbiological testing and outcome of patients with severe community-acquired pneumonia[J].Chest,2003,123(1):174-180.
7[7]Valles J,Mesalles E,Mariscal D,et al.A 7-year study of severe hospital-acquired pneumonia requiring ICU admission[J].Intensive Care Med,2003,29(11):1981-1988.
8[8]Wilson PA,Ferguson J.Severe community-acquired pneumonia:an Australian perspective[J].Intern Med J,2005,35(12):699-705.
9[9]Martinez JA,Horcajada JP,Almela M,et al.Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia[J].Clin Infect Dis,2003,36(4):389-395.
10[10]Baddour LM,Yu VL,Klugman KP,et al.Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia[J].Am J Respir Crit Care Med,2004,170(4):440-444.
